Sole Challenger HEC Beaten On US Gilenya Patent

Key Patent to December 2027 Upheld

Courtroom
HEC's dual challenge to Gilenya's dosage-regimen patent fell flat • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin